Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01814631
Other study ID # 409829
Secondary ID
Status Withdrawn
Phase N/A
First received March 18, 2013
Last updated April 12, 2016
Start date March 2013
Est. completion date June 2013

Study information

Verified date April 2016
Source Florida Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The primary objective for this study is to compare the image quality of two endoscopic ultrasound (EUS) processors used for imaging of the pancreas. Processor images are used to make a correct clinical diagnosis and higher quality imaging is related to more accurate results. Patient care may be improved due to the information collected as part of this study.

The quality of imaging is of utmost importance for diagnosing early neoplasms in the pancreas and diseases such as chronic pancreatitis. Image quality is dictated by two factors: image resolution and depth of penetration. Good imaging enables diagnosis of early stage disease and thereby facilitates early treatment.


Description:

The endoscope is usually connected to a processor that generates an image which is viewed on a monitor. At FH, we use a processor called Aloka 10. A new processor is being developed by Olympus Corporation called EU-ME 2. This new processor is FDA approved, but has not been launched commercially yet. It has been loaned to FH for evaluation. We would like to evaluate this processor in an objective manner and hence the request for study approval.

In this study, the endoscopy during the procedure will be attached to two different processors and images will be generated. The choice of which processor will be used first will be at the discretion of the Endoscopist. This does not require removal and reintroduction of the endoscope into the patient at two occasions. Only the connector will be switched to a different processor. So there is negligible risk to the patient.

The time required for research activities will be between 5-10 minutes. Both processors will be set up in the procedure room for the duration of this study.

The physician will then document the depth of penetration of the image (the farthest structure seen) and image resolution (evaluating the pancreas for subtle abnormalities). Both processors will be used for each patient. The scores for each processor will be documented to a procedure log, using the primary endpoint described above. The CRF will not have any patient information. Images viewed by the physician at the time of procedure will not be saved or recorded as part of this study..

EUS will be performed in the standard fashion by one of the experienced endosonographers in the unit. Once the EUS is complete, the procedure will be stopped and the echoendoscope withdrawn from the patient.

Patients will then be transported to the recovery area for observation as per standard policy. After appropriate observations are deemed satisfactory, patients will be discharged as per unit policy.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2013
Est. primary completion date May 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 19 Years to 89 Years
Eligibility Inclusion Criteria:

All patients referred to Florida Hospital Endoscopy Unit for assessment of pancreas will be included.

Exclusion Criteria:

Age <19 years Unable to safely undergo EUS for any reason

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Other:
image quality and resolution
Image quality and resolution will be viewed using Aloka processor
image quality and resolution
image quality and resolution will be viewed on the EU-me2

Locations

Country Name City State
United States Florida Hospital Orlando Florida

Sponsors (1)

Lead Sponsor Collaborator
Florida Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary image quality The primary endpoint of the study is to compare processors by assessing image resolution and depth of penetration. This will be accomplished using a objective scoring system assigning one point for each structure visualized. This score will range from 0 to a maximum of 9. up to 2 months No
See also
  Status Clinical Trial Phase
Recruiting NCT03609944 - SpHincterotomy for Acute Recurrent Pancreatitis N/A
Not yet recruiting NCT04652271 - International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
Completed NCT01441492 - Pancreas Resection With and Without Drains N/A
Recruiting NCT02196935 - Los Angeles Prospective GI Biliary and EUS Series
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01545167 - The North American Pancreatitis Study N/A
Completed NCT04168801 - Early Oral Refeeding in Mild Acute Pancreatitis N/A
Recruiting NCT03334708 - A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Completed NCT01824186 - Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy N/A
Terminated NCT00428025 - Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients Phase 4
Completed NCT00639314 - Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy N/A
Recruiting NCT00160836 - Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter Phase 1
Completed NCT00121901 - Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis? Phase 3
Completed NCT00999232 - Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube Phase 4
Terminated NCT00419549 - Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP) Phase 2/Phase 3
Active, not recruiting NCT05095831 - EUS Shear Wave for Solid Pancreatic Lesions.
Completed NCT03601325 - Acute Pancreatitis: Study of Possible Etiologies and Risk Factors Affecting Outcome
Withdrawn NCT02465138 - A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis Phase 4
Not yet recruiting NCT06133023 - WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts N/A
Recruiting NCT02971475 - ESWL Versus ESWL and Endoscopic Treatment N/A